Dainippon Sumitomo Results Driven By Strong Revenue Growth In North America
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo said that despite the end of some production contracts and reduced industrial property rights domestically, the company’s atypical antipsychotic drug Latuda aided by the weak yen led to double-digit growth in North America.